Myriad Genetics unveils MyRisk test for hereditary colorectal cancer management

Myriad Genetics unveils MyRisk test for hereditary colorectal cancer management
Myriad launches MyRisk for CRC care

Myriad Genetics has introduced its MyRisk Hereditary Cancer Test designed to provide clear, guideline-aligned recommendations in managing lifelong colorectal cancer (CRC) care.

The test aims to support both patients and their families by informing decisions on surveillance intensity, second cancer screening, and specialty care post-surgery. The initiative targets ongoing CRC patient management, not just surgical outcomes, seeking to optimize preventive strategies and improve quality of care.

The company recently launched an AI enhanced test for active surveillance, focusing on improved management in urology and prostate cancer care. Myriad is also set to roll out the Prolaris plus AI Test, which combines molecular scores with digital pathology for prostate cancer diagnosis. These moves expand Myriad Genetics’ portfolio of risk assessment tools across cancer indications.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.